Co-Authors
This is a "connection" page, showing publications co-authored by PAUL W GIDLEY and FRANCO DEMONTE.
Connection Strength
3.925
-
Middle cranial fossa approach for acoustic neuroma. Neurosurg Focus Video. 2021 Oct; 5(2):V12.
Score: 0.799
-
Temporal bone malignancies. Neurosurg Clin N Am. 2013 Jan; 24(1):97-110.
Score: 0.436
-
Hearing preservation surgery for vestibular schwannoma: experience with the middle fossa approach. Neurosurg Focus. 2012 Sep; 33(3):E10.
Score: 0.426
-
Losartan May Not Prevent Vestibular Schwannoma Growth or Related Hearing Loss During Observation. Otol Neurotol. 2024 Jul 01; 45(6):690-695.
Score: 0.242
-
The Effect of Metformin on Vestibular Schwannoma Growth: A Systematic Review and Meta-analysis. Laryngoscope. 2023 09; 133(9):2066-2072.
Score: 0.219
-
Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology. J Exp Clin Cancer Res. 2022 Oct 04; 41(1):292.
Score: 0.214
-
Osteoblastoma of the Temporal Bone in a Child. Otol Neurotol. 2022 02 01; 43(2):e276-e278.
Score: 0.204
-
Site-Specific Considerations in the Surgical Management of Skull Base Chondrosarcomas. Oper Neurosurg (Hagerstown). 2018 06 01; 14(6):611-619.
Score: 0.158
-
Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. J Neurosurg. 2019 03 01; 130(3):812-821.
Score: 0.157
-
Multimodality Treatment of Skull Base Chondrosarcomas: The Role of Histology Specific Treatment Protocols. Neurosurgery. 2017 Sep 01; 81(3):520-530.
Score: 0.150
-
Nonmelanoma cutaneous cancers involving the skull base: outcomes of aggressive multimodal management. J Neurosurg. 2015 Sep; 123(3):781-8.
Score: 0.128
-
Radiation-associated malignancies of the ear canal and temporal bone. Laryngoscope. 2015 May; 125(5):1198-204.
Score: 0.124
-
The natural history of primary temporal bone myxoma. Ann Diagn Pathol. 2012 Aug; 16(4):280-3.
Score: 0.103
-
The oncology of otology. Laryngoscope. 2012 Feb; 122(2):393-400.
Score: 0.102
-
Predictors of postoperative performance status after surgical management of infratemporal fossa malignancies. Neurosurg Rev. 2023 Jun 29; 46(1):157.
Score: 0.056
-
Post-Treatment Imaging Evaluation of the Skull Base. Semin Roentgenol. 2023 07; 58(3):217-236.
Score: 0.056
-
Patient, Disease, and Treatment-Related Factors Affecting Progression-Free and Disease-Specific Survival in Recurrent Chondrosarcomas of the Skull Base. Oper Neurosurg (Hagerstown). 2023 01 01; 24(1):33-43.
Score: 0.054
-
Surgical Management of Skull Base Osteoradionecrosis in the Cancer Population - Treatment Outcomes and Predictors of Recurrence: A Case Series. Oper Neurosurg (Hagerstown). 2020 09 15; 19(4):364-374.
Score: 0.046
-
Surgical management of carcinomas of the infratemporal fossa and skull base: patterns of failure and predictors of long-term outcomes. J Neurosurg. 2021 05 01; 134(5):1392-1398.
Score: 0.046
-
Management of Recurrent or Progressing Skull Base Chondrosarcomas: Predictors of Long-Term Outcomes. J Neurol Surg B Skull Base. 2021 Jul; 82(Suppl 3):e155-e165.
Score: 0.045
-
Impact of early access to multidisciplinary care on treatment outcomes in patients with skull base chordoma. Acta Neurochir (Wien). 2018 04; 160(4):731-740.
Score: 0.038
-
The First Reported Case of Primary Intestinal-type Adenocarcinoma of the Middle Ear and Review of the Literature. Otol Neurotol. 2017 10; 38(9):e364-e368.
Score: 0.038
-
Petroclival Chondrosarcoma: A Multicenter Review of 55 Cases and New Staging System. Otol Neurotol. 2016 08; 37(7):940-50.
Score: 0.035
-
Skull base reconstruction: an updated approach. Plast Reconstr Surg. 2011 Sep; 128(3):675-686.
Score: 0.025
-
Radiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e819-23.
Score: 0.024